It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays. We’ll discuss individual Dogs—and their divvies—in a moment. First ...

In May 2024, Amgen reported its TCE antibody, Tarlatamab (brand name IMDELLTRA), which targets small cell lung cancer has achieved FDA accelerated approval for market release.

William Blair also expressed optimism about Amgen’s broader portfolio, citing revenue upside potential from key assets including Repatha, Imdelltra, and Uplizna, while success with late-stage ...

William Blair also maintained an Outperform rating, highlighting the potential revenue growth from Amgen’s broader portfolio, including drugs like Repatha and Imdelltra.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...